<?xml version="1.0" encoding="UTF-8"?>
<GaPExchange xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="dbGaPEx2.1.5.xsd">

<MetaVariables>
	<Submitter/>
	<Method/>
</MetaVariables>
<MetaLinks/>

<Projects>
	<Project/>
</Projects>

<Studies>

<Study source="dbGaP" accession="phs000504.v1.p1" parentStudy="phs000504.v1.p1" createDate="2012-06-05" modDate="2012-07-27">

<Configuration>
	<Data_Provider><![CDATA[
		<table border="1">
		<tr><th>Title</th><th>Name</th><th>Institute</th></tr>
		<tr><td>Principal Investigators</td><td>Matthew Meyerson</td><td>Broad Institute, Cambridge MA, Dana Farber Cancer Institute, Boston MA, USA</td></tr>
		<tr><td>Principal Investigators</td><td>Scott Pomeroy</td><td>Children&#39;s Hospital, Boston, MA, USA</td></tr>
		<tr><td>Principal Investigators</td><td>Yoon-Jae Cho</td><td>Stanford University School of Medicine and Lucile Packard Children&#39;s Hospital, Palo Alto, CA, USA</td></tr>
		<tr><td>Funding Source</td><td>NHGRI</td><td>National Human Research Institute, National Institutes of Health, Bethesda, MD, USA</td></tr>
		</table>
	]]></Data_Provider>
	<StudyNameEntrez>Genomic Sequencing of Medulloblastoma</StudyNameEntrez>
	<StudyNameReportPage>Genomic Sequencing of Medulloblastoma</StudyNameReportPage>
	<StudyTypes>
		<StudyType>Case Set</StudyType>
	</StudyTypes>
	<Description><![CDATA[
<p>Medulloblastomas are the most common malignant brain tumors in children. Identifying and understanding the genetic events that drive these tumors is critical for the development of more effective diagnostic, prognostic and therapeutic strategies. Recently, our group and others described distinct molecular subtypes of medulloblastoma based on transcriptional and copy number profiles. Here, we utilized whole exome hybrid capture and Illumina sequencing to identify somatic mutations across the coding regions of 92 primary medulloblastoma/normal pairs. Overall, medulloblastomas exhibit low mutation rates consistent with other pediatric tumors, with a median of 0.35 non-silent mutations per megabase. We identified twelve genes mutated at statistically significant frequencies, including previously known mutated genes in medulloblastoma such as <i>CTNNB1</i>, <i>PTCH1</i>, <i>MLL2</i>, <i>SMARCA4</i> and <i>TP53</i>. Recurrent somatic mutations were identified in an RNA helicase gene, <i>DDX3X</i>, often concurrent with <i>CTNNB1</i> mutations, and in the nuclear co-repressor (N-CoR) complex genes <i>GPS2</i>, <i>BCOR</i>, and <i>LDB1</i>, to our knowledge novel findings in medulloblastoma and all cancer. We show that mutant <i>DDX3X</i> potentiates transactivation of a TCF promoter and enhances cell viability in combination with mutant but not wild type beta-catenin. Together, our study reveals the alteration of Wnt, Hedgehog, histone methyltransferase and now <i>N-CoR</i> pathways across medulloblastomas and nominates the RNA helicase <i>DDX3X</i> as a component of pathogenic beta-catenin signaling in medulloblastoma.</p> <p>"Reprinted from &#39;MEDULLOBLASTOMA EXOME SEQUENCING UNCOVERS SUBTYPE-SPECIFIC SOMATIC MUTATION&#39;, with permission from Nature" </p>]]>
	</Description>
	<StudyProjects>
		<Project/>
	</StudyProjects>
	<Publications>
		<Publication>
			<Pubmed pmid="22820256"/>
		</Publication>
	</Publications>
	<Diseases>
		<Disease vocab_source="MESH" vocab_term="Medulloblastoma"/>
	</Diseases>
	<Attributions>
		<Header title="Principal Investigators">
			<AttName>Matthew Meyerson</AttName>
			<Institution>Broad Institute, Cambridge MA, Dana Farber Cancer Institute, Boston MA, USA</Institution>
		</Header>
		<Header title="Principal Investigators">
			<AttName>Scott Pomeroy</AttName>
			<Institution>Children&#39;s Hospital, Boston, MA, USA</Institution>
		</Header>
		<Header title="Principal Investigators">
			<AttName>Yoon-Jae Cho</AttName>
			<Institution>Stanford University School of Medicine and Lucile Packard Children&#39;s Hospital, Palo Alto, CA, USA</Institution>
		</Header>
		<Header title="Funding Source">
			<AttName>NHGRI</AttName>
			<Institution>National Human Research Institute, National Institutes of Health, Bethesda, MD, USA</Institution>
		</Header>
	</Attributions>
	<DisplayPublicSummary>yes</DisplayPublicSummary>
	<ConsentGroups>
		<ConsentGroup groupNum="1" shortName="CRO" longName="Cancer Research Only"/>
	</ConsentGroups>
</Configuration>

  <AuthorizedAccess>
    <DacInfo ssDacId="0">
      <DacName>NHGRI</DacName>
      <DacFullName>National Human Genome Research Institute</DacFullName>
      <DacEmail>0</DacEmail>
      <DacPhone></DacPhone>
      <DacUrl></DacUrl>
    </DacInfo>
    <Policy Policy_ID="phs000504.v1.p1_policy" ref_ssDacId="0">
      <DisplayResearchStatement>yes</DisplayResearchStatement>
      <DisplayPublicSummary>yes</DisplayPublicSummary>
      <EmbargoLength>0</EmbargoLength>
      <YearsUntilRenewal>1</YearsUntilRenewal>
      <WeeksCancelRequest>8</WeeksCancelRequest>
      <PdfSupplementReqired>no</PdfSupplementReqired>
      <AcknowledgementText>
        <para>
          http://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs000504.v1.p1
        </para>
      </AcknowledgementText>
      <DocumentSet>
        <DataUseCertificate Label="Data Use Certificate" FilePath="https://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs000504.v1.p1" FileName="LANDERMedulloblastoma_Cancer_FINAL_DUC_05_29_2012.pdf"/>
      </DocumentSet>
    </Policy>
    <ConsentGroups>
      <ParticipantSet groupNum-REF="1">
        <ConsentName>Cancer Research Only</ConsentName>
        <ConsentAbbrev>CRO</ConsentAbbrev>
        <UseLimitation>Cancer Research Only</UseLimitation>
        <IrbRequired>No</IrbRequired>
      </ParticipantSet>
    </ConsentGroups>
  </AuthorizedAccess>


</Study>

</Studies>

</GaPExchange>
